Clinical Data Transparency

The Clinical Data Transparency Initiative was formed with a mission of developing a model approach for redacting privacy information found in clinical study reports and a model approach for the anonymization of patient-level data shared with the broader healthcare community. The Clinical Data Transparency Initiative is completed. There are no new solutions or updates planned.

As of June 2019, the TransCelerate Clinical Data Transparency (CDT) initiative has successfully completed all initiative objectives, with two assets transitioned to PHUSE and the remaining asset to be maintained by TransCelerate’s Clinical Research Access & Information Exchange. No new deliverables are planned.

As regulators and other stakeholders push the industry towards increased transparency, there is a need for a viable approach to increase transparency while protecting the privacy of individuals involved in clinical trials. TransCelerate’s Clinical Data Transparency (CDT) Initiative was formed with a mission enabling ready compliance with regulations designed to enhance transparency and facilitate future research while preserving the privacy of patients, investigators and clinical trial staff.

The CDT Initiative authored assets that provide guidance and model approaches for redacting privacy information found in clinical study reports, anonymizing patient level data shared with the broader healthcare community and preparing and distributing layperson summaries to the general public and clinical study participants.

The revised papers Protection of Personal Data in Clinical Documents – A Model Approach and De-identification and Anonymization of Individual Patient Data in Clinical Studies – A Model Approach can now be found on PHUSE’s website. PHUSE will continue to update the papers as needed. PHUSE was well-positioned to own these bodies of work as it can leverage a broader set of stakeholders around the globe to facilitate increased holistic thinking around these assets so these papers can live on in the R&D ecosystem.

The layperson summaries can be found on TransCelerate’s Clinical Research Access & Information Exchange solutions page.

All of our Initiatives develop practical solutions to overcome inefficiencies in clinical trials, nonclinical studies, and drug safety. Learn more by exploring our work.

Related Initiatives

Clinical Research Access & Information Exchange

Clinical Research Access & Information Exchange seeks to provide a better window into information about clinical research and trial options and to contribute to a more rewarding clinical trial experience via better exchange of information with trial participants.

Clinical Content & Reuse

What’s New CC&R Initiative & Solutions  With the 2024 Release, the Clinical Template Suite (CTS) continues to reflect state of the art research trends and guidance while successfully reaching its value and impact goals. Those being: While future plans for CTS template revisions are evolving, their place in the clinical trial ecosystem is undeniable and…

Risk Based Monitoring

The Risk Based Monitoring Initiative was established in 2012 as one of the five initial goals created by TransCelerate to drive efficient and effective solutions into the R&D industry. Clinical trial sites have varying levels of experience and quality, but monitoring approaches are not designed to manage potential differences.